UOC
DXCM icon

UBS O'Connor’s DexCom DXCM Stock Holding History

UBS O'Connor’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$25.9K – 534
2024
Q2 		$25.9K Buy
+15,000
New +$1.9M ﹤0.01% 470

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS O'Connor's DXCM Position: Q3 2025 in Review

UBS O'Connor sold out of DexCom (DXCM) in Q3 2025, closing a stake of 35,668 shares — an estimated $3.11M sold.

UBS O'Connor first reported a position in DXCM in Q3 2023 and held it in 7 quarters. The position peaked at $3.11M in Q2 2025. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • UBS O'Connor reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 35,668 DexCom shares in Q3 2025, an estimated $3.11M.
  • UBS O'Connor first reported a position in DexCom in Q3 2023 and held it in 7 quarters.
  • UBS O'Connor's DexCom position peaked at $3.11M in Q2 2025.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.